{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:33:58Z","timestamp":1787772838246,"version":"build-2784847793"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Rituximab is slowly getting recognized as a promising steroid-sparing agent in the treatment of moderate to severe cases of pemphigus vulgaris (PV). We evaluated and compared the effectiveness, safety, and cost of therapy of rituximab versus dexamethasone cyclophosphamide pulse (DCP) in Indian patients with PV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>It is a retrospective data analysis, from the Immunobullous disease clinic in a tertiary centre of eastern India, of management of PV. In our institute we use either rituximab or DCP for the management of moderate to severe cases of PV, depending on that we retrospectively divided the treated cases of PV in two groups. Patients who were treated with rheumatoid arthritis (RA) protocol of rituximab were considered to be group 1. Patients who were treated with DCP were included in group 2. Response was assessed by pemphigus area, and activity score (PAAS), Dermatology life quality index (DLQI); photographic documentation, and blood parameters were monitored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Both groups showed significant improvement in PAAS and DLQI, the improvement was faster and well sustained in the rituximab group. In terms of safety and development of new vesicles, rituximab had a better profile with only 1 patient having adverse effects and none with new vesicles as compared to DCP (3 had adverse effects and 2 developed new vesicles).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Rituximab offers the advantage of early and prolonged remission, lesser adverse effects, better effectiveness, less risk of relapses, faster improvement of PAAS, and DLQI. Though rituximab is an expensive drug, but on evaluating the cost of whole therapy, it was seen that rituximab infusions are actually cheaper compared to DCP pulse. We suggest, rituximab can be used as the first-line of therapy for pemphigus vulgaris in the Indian context.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijd.ijd_306_20","type":"journal-article","created":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T12:52:07Z","timestamp":1623156727000},"page":"223","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["A Comparative Study to Evaluate the Efficacy and Cost of Rituximab versus Dexamethasone Cyclophosphamide Pulse in Patients of Pemphigus Vulgaris"],"prefix":"10.4103","volume":"66","author":[{"given":"Sudip","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komal","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonal","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepika","family":"Halder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujata","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"De","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-28-20240829","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/1096-8652(200102)66:2<142::AID-AJH1032>3.0.CO;2-0","article-title":"Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: Report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL","volume":"66","author":"Heizmann","year":"2001","journal-title":"Am J Hematol"},{"key":"R2-28-20240829","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2011.04391.x","article-title":"Efficacy and safety of rituximab treatment in Indian pemphigus patients","volume":"27","author":"Kanwar","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R3-28-20240829","doi-asserted-by":"crossref","first-page":"367","DOI":"10.4103\/idoj.IDOJ_290_18","article-title":"Rituximab in pemphigus: Road covered and challenges ahead","volume":"9","author":"Vinay","year":"2018","journal-title":"Indian Dermatol Online J"},{"key":"R4-28-20240829","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.jaad.2010.06.033","article-title":"Rituximab used as a first-line single agent in the treatment of pemphigus vulgaris","volume":"65","author":"Craythorne","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"R5-28-20240829","first-page":"342","article-title":"Pemphigus in Goa","volume":"92","author":"Mascarenhas","year":"1994","journal-title":"J Indian Med Assoc"},{"key":"R6-28-20240829","first-page":"126","article-title":"A clinicopathological study of Pemphigus","volume":"39","author":"Singh","year":"1973","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R7-28-20240829","first-page":"5","article-title":"Pemphigus in India. A note","volume":"18","author":"Sehgal","year":"1972","journal-title":"Indian J Dermatol"},{"key":"R8-28-20240829","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/7140.2006.00010","article-title":"Pemphigus in North India","volume":"10","author":"Kanwar","year":"2006","journal-title":"J Cutan Med Surg"},{"key":"R9-28-20240829","doi-asserted-by":"crossref","first-page":"439","DOI":"10.4103\/0378-6323.82396","article-title":"Pemphigus in India","volume":"77","author":"Kanwar","year":"2011","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R10-28-20240829","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1038\/jid.2008.330","article-title":"Rituximab immunotherapy in pemphigus: Therapeutic effects beyond B-cell depletion","volume":"128","author":"Zambruno","year":"2008","journal-title":"J Invest Dermatol"},{"key":"R11-28-20240829","first-page":"WC01","article-title":"Rituximab: A magic bullet for pemphigus","volume":"11","author":"Anandan","year":"2017","journal-title":"J Clin Diagn Res"},{"key":"R12-28-20240829","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4103\/CDR.CDR_42_17","article-title":"Outcome of pulse therapy in pemphigus: A 10 year study","volume":"2","author":"Varala","year":"2018","journal-title":"Clin Dermatol Rev"},{"key":"R13-28-20240829","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jaad.2012.08.010","article-title":"Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: A retrospective study of 47 patients","volume":"68","author":"Leshem","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"R14-28-20240829","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1365-4632.2012.5847.x","article-title":"Adjuvant rituximab in the treatment of pemphigus vulgaris: A phase II clinical trial","volume":"52","author":"Balighi","year":"2013","journal-title":"Int J Dermatol"},{"key":"R15-28-20240829","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1001\/jamadermatol.2013.6739","article-title":"Durable remission of pemphigus with a fixed-dose rituximab protocol","volume":"150","author":"Heelan","year":"2014","journal-title":"JAMA Dermatol"},{"key":"R16-28-20240829","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.autrev.2014.12.002","article-title":"A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab","volume":"14","author":"Ahmed","year":"2015","journal-title":"Autoimmun Rev"},{"key":"R17-28-20240829","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s002770000163","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: Results of a phase-II study of the German Low-Grade Lymphoma Study Group","volume":"79","author":"Feuring-Buske","year":"2000","journal-title":"Ann Hematol"},{"key":"R18-28-20240829","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1186\/ar3337","article-title":"Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: Experience from a national registry (GRAID)","volume":"13","author":"Tony","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"R19-28-20240829","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1749-6632.2009.04744.x","article-title":"Rituximab in severe pemphigus","volume":"1173","author":"Schmidt","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"R20-28-20240829","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/10428194.2011.608446","article-title":"Progressive multifocal leukoencephalopathy after treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia","volume":"53","author":"Herold","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"R21-28-20240829","doi-asserted-by":"crossref","first-page":"128","DOI":"10.4103\/0378-6323.39696","article-title":"Premature ovarian failure due to cyclophosphamide: A report of four cases in dermatology practice","volume":"74","author":"Saoji","year":"2008","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R23-28-20240829","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4103\/0378-6323.53133","article-title":"Outcome of dexamethasone-cyclophosphamide pulse therapy in pemphigus: A case series","volume":"75","author":"Kandan","year":"2009","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R24-28-20240829","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1365-4632.2005.02218.x","article-title":"Twelve-year clinico-therapeutic experience in pemphigus: A retrospective study of 54 cases","volume":"44","author":"Mahajan","year":"2005","journal-title":"Int J Dermatol"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.IJD_306_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:14:32Z","timestamp":1787771672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.IJD_306_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_306_20","relation":{},"ISSN":["0019-5154"],"issn-type":[{"value":"0019-5154","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]}}}